Ecosystem
Beta Site
August 2022
"CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended June 30, 2022 and provided an overview of its recent operational highlights." Read more at the source
November 2022 "Neuropeptides produce robust effects on behavior across species, and recent research has benefited from advances in...
November 2022 "Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling...
November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...
Comments